Développement De La Stimulation Non-invasive En Boucle Fermée
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Non-invasive Brain Stimulation
- Sponsor
- University Hospital, Grenoble
- Enrollment
- 60
- Primary Endpoint
- Quality of EEG markers extracted in real-time
- Status
- Not yet recruiting
- Last Updated
- last year
Overview
Brief Summary
Transcranial magnetic stimulation (TMS) is a widely used tool for exploring brain function in humans (Siebner et al. et al., 2022), which has led to new therapeutics for various psychiatric and neurological disorders (Lefaucheur et al., 2020). However, the open-loop use of this technique has raised questions about its operating principle, due to the high degree of heterogeneity of results and the small to medium observed effect sizes (Zrenner and Ziemann, 2023). To increase the response rate, it has been suggested to individualize stimulation, by adapting the TMS parameters (i.e. delivered dose, target dose, targeting, timing, etc.) to instantaneous estimates of brain brain state. Such an approach, known as closed-loop closed-loop stimulation, is currently one of the main challenges challenges in this field (closed-loop brain state-dependent stimulation). To this end, we are focusing on the combination of robotic TMS and electroencephalography (EEG) (Hernandez-Pavon et al. al., 2023). The closed-loop stimulations using this combination developed to date have two limitations: (i) they are not adaptive and focus focus mainly on calculating the phase of brain oscillations to trigger stimulation and (ii) are limited to central cortical (sensorimotor) areas, where the EEG signal-to-noise ratio is optimal.
This project aims to develop closed-loop TMS-EEG protocols that overcome these two limitations: (i) by incorporating adaptive decision modeling (AutoHS model, Harquel et al. 2017) to optimize several parameters in parallel (coil location, orientation, intensity) while using a wider range of EEG markers (evoked potentials, oscillatory activity strength, connectivity, etc.), and (ii) by integrating real-time EEG pre-processing to access any cortical target (including frontal, temporal and occipital lobes).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Signed informed consent
- •Having undergone a medical examination prior to participation in research
- •Affiliation with or beneficiary of a social security scheme
Exclusion Criteria
- •Contraindications (CI) to MRI, EEG, TMS practice
- •Existence of a severe general medical condition: cardiac, respiratory, hematological, renal, hepatic, cancerous,
- •Regular use of anxiolytics, sedatives, antidepressants, neuroleptics,
- •Characterized psychiatric pathology,
- •Suspicion of alcohol ingestion prior to the examination,
- •Participation in other interventional research protocols in progress with exclusion period or in the preceding week.
- •Persons covered by articles L1121-5 to L1121-8 of the CSP (French Public Health Code) (corresponds to all protected persons: pregnant women, parturients, nursing mothers, persons deprived of their liberty by judicial or administrative decision, persons under psychiatric care under articles L.
- •3212-1 and L. 3213-1 who are not covered by the provisions of article L. 1121-8, persons admitted to a health or social establishment for purposes other than research, minors, persons under legal protection or unable to express their consent).
- •Personnel with a hierarchical link to the principal investigator
Outcomes
Primary Outcomes
Quality of EEG markers extracted in real-time
Time Frame: During the two TMS-EEG experimental sessions, at day 0 and up to day 30
Quality of EEG markers extracted in real-time (evoked potentials, power and phase of brain oscillations and functional connectivity)
Quality of EEG marker modulation
Time Frame: During the two TMS-EEG experimental sessions, at day 0 and up to day 30
Quality of EEG marker modulation induced by TMS parameters selected by the AutoHS decision model
Secondary Outcomes
- Intra-individual (inter-session) reproducibility of primary endpoint quality markers(Contrast between the 2 TMS-EEG experimental sessions, at day 0 up to day 30)